Navigation Links
Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
Date:5/11/2009

orward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave or Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; the potential that earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual prope
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
2. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
3. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
4. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
(Date:7/10/2014)... for crude 3-D glasses, polarized glasses, and shutter ... devices, used to trick the brain into perceiving ... obsolete with the introduction of new holography technology ... doctoral students Yuval Yifat, Michal Eitan, and Zeev ... nanoantennas that could be used for security as ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... in the late 1970s with the first IPOs taking place in ... than 25 years old. , ,An interesting article in Genetic ... that most industry cycles run about 50 years until they mature. ... 50-year cycle. A new industry of significance usually produces an industrial ...
... In a long-planned departure from its traditional focus, high-end ... the U.S. Army for development of two different products. ... that it has secured $2.2 million in federal contracts ... with the Armys Research, Development and Engineering Command (CERDEC) ...
... Mike Strand has always kept his eye out ... Delta Technology and Cray Research, Strand took a stride forward ... company based out of his home dealing with barcode software. ... had expanded into a worldwide enterprise bringing in close to ...
Cached Biology Technology:Biotech industry reaches midpoint in 50-year maturation cycle 2Biotech industry reaches midpoint in 50-year maturation cycle 3Biotech industry reaches midpoint in 50-year maturation cycle 4Biotech industry reaches midpoint in 50-year maturation cycle 5SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Online Kiosks founder Mike Strand uses contest to screen new business plan 2Online Kiosks founder Mike Strand uses contest to screen new business plan 3
(Date:7/11/2014)... the Wildlife Conservation Society shows that no-take zones ... species such as lobster, conch, and fish recover ... reef areas. , The reporttitled "Review of the ... research literature from no-take areas around the world. ... a recognized expert in marine protected areas and ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... South Wales, Australia when NASA,s Aqua satellite passed overhead ... 11 (12:35 p.m. local time/11:35 p.m. EDT on July ... (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard captured ... smoke (light brown) from various fires. Actively burning areas, ... , The New South Wales, Australia Government website "NSW ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... leading provider of,embedded speech solutions today announced the ... AG, according to SVOX CEO Volker Jantzen.,SVOX has ... developed,over 25 years, including the SpeechAdvance(TM) speech recognition ... majority of the Professional,Speech Processing Group,s employees will ...
... MAYWOOD, Ill. -- Most people know that too much sodium ... suggests that people trying to lower their blood pressure should ... effect to sodium. Researchers found that the ratio of ... cardiovascular disease than sodium or potassium alone. "There ...
... officials from the U.S. National Science Foundation and the ... today marked the occasion of the research vessel JOIDES ... and transit to Honolulu, after a complete transformation to ... The JOIDES Resolution is the U.S. research ...
Cached Biology News:SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2Cutting salt isn't the only way to reduce blood pressure 2Ocean research officials hail completion of modernization for US scientific ocean drilling vessel 2
Human PLUNC Biotinylated Affinity Purified PAb...
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
... polyclonal to GRASP1 ( Abpromise ... Antigen: Synthetic peptide corresponding ... C terminal region of rat GRASP1, ... Entrez GeneID: ...
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Biology Products: